by Truveta staff | Jul 30, 2024 | Technology
By the time most women with ovarian cancer are diagnosed, 70-80% are already at an advanced stage of the disease. Despite declining mortality rates over the past decade, the 5-year survival rate for patients with ovarian cancer remains less than 30%. Sometimes...
by Truveta Research | Jun 10, 2024 | Research, Research Insights
There are mixed prostate-specific antigen (PSA) screening recommendations for men of varying ages. The objective of this study was to describe variation in first-time PSA values across demographic and SDOH factors. In a study of nearly 4 million men with PSA lab...
by Truveta staff | May 20, 2024 | Data
You probably know someone who will be diagnosed with prostate cancer in their lifetime. 1 in 8 men will develop prostate cancer, with a higher risk in Black and African American men and an overall increased risk after the age of 65. While most cases are not fatal,...
by Truveta staff | Sep 12, 2023 | News
Medical Components, Inc. and Truveta are partnering to advance the use of real-world data to improve clinical care for patients battling cancer and kidney disease who require advanced vascular access for treatment. Truveta delivers the most complete, timely, and clean...
